Evaxion Biotech hosts a Research & Development Day focusing on its core AI-Immunology platform. The event will be hosted at our facilities in Horsholm, Denmark, between 14.00 – 18.00 CET / 9.00 a.m. – 1.00 p.m. EST and can be accessed remotely here. Christian Kanstrup, CEO of Evaxion, expresses enthusiasm: “We have been looking forward to this exciting day and welcome everyone interested in learning more about our technology and its potential for saving and improving lives. We believe that we hold a truly differentiated position driven by our validated AI-Immunology(TM) platform and the multi-disciplinary capability set we have built around it. The potential of AI-Immunology(TM) is evidenced by our strong pipeline of vaccine candidates and existing partnerships.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EVAX:
- Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
- Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations
- Evaxion announces completion of initial phases of collaboration with MSD
- Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
- Evaxion Biotech initiated with a Buy at H.C. Wainwright
